AstraZeneca reports 'positive' cardiovascular results from Brilinta and Farxiga drugs
2nd Sep 2019 07:41
(Sharecast News) - AstraZeneca on Monday reported a duo of "positive" results, including a trial that showed its cardiovascular drug, Brilinta, when combined with Aspirin, reduced the relative risk of heart attack or stroke by 10% when compared with aspirin alone.
Read moreAstraZeneca sees positive results from latest 'anifrolumab' trial
29th Aug 2019 07:29
(Sharecast News) - AstraZeneca announced on Thursday that the phase 3 'TULIP 2' trial for 'anifrolumab' - a potential new medicine for the treatment of systemic lupus erythematosus (SLE) - met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo, with both arms receiving standard of care.
Read moreWednesday broker round-up
28th Aug 2019 12:43
(Sharecast News) - Greggs: UBS upgrades to buy with a target price of 2,300p.
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca granted marketing authorisation for Roxadustat in China
22nd Aug 2019 08:21
(Sharecast News) - Biopharmaceutical company AstraZeneca has received marketing authorisation for Roxadustat in China for the treatment of anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
Read moreAstraZeneca drug fails to improve on chemotherapy in lung cancer trial
21st Aug 2019 07:22
(Sharecast News) - AstraZeneca confirmed on Wednesday that its Imfinzi (durvalumab) treatment for lung and bladder cancer failed to improve upon survival rates registered by chemotherapy treatment in a clinical trial where it was combined with a human monoclonal antibody.
Read moreAstraZeneca upbeat on latest 'Forxiga' trial outcomes
20th Aug 2019 07:27
(Sharecast News) - AstraZeneca announced positive results from its phase 3 'DAPA-HF' trial on Tuesday, which showed that 'Farxiga' (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular death or worsening of heart failure - defined as hospitalisation or an urgent heart failure visit - compared to placebo.
Read more